Compare DCOMP & NUWE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DCOMP | NUWE |
|---|---|---|
| Founded | N/A | 1999 |
| Country | United States | United States |
| Employees | 887 | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 2.9M |
| IPO Year | N/A | N/A |
| Metric | DCOMP | NUWE |
|---|---|---|
| Price | $18.00 | $2.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 40.7K |
| Earning Date | N/A | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,167,999.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10.48 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $2.01 |
| 52 Week High | N/A | $70.14 |
| Indicator | DCOMP | NUWE |
|---|---|---|
| Relative Strength Index (RSI) | 34.20 | 38.24 |
| Support Level | $17.82 | $2.02 |
| Resistance Level | $18.28 | $2.20 |
| Average True Range (ATR) | 0.25 | 0.17 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 10.53 | 0.47 |
Dime Community Bancshares Inc operates as a holding company. It gathers deposits from customers within its market area and via the internet and invests them in multifamily residential, commercial real estate, commercial and industrial (C&I) loans, and one-to-four family residential real estate loans, as well as mortgage-backed securities, obligations of the U.S. government and government- sponsored enterprises (GSEs), and corporate debt and equity securities. The company has one reportable segment which is Community Banking.
Nuwellis Inc is a medical technology company focused on developing, manufacturing, and commercializing a medical device used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems. The Aquadex Smartflow System removes excess fluid from patients suffering from fluid overload who have not responded to medical management, including diuretics. Nuwellis has one reportable segment: fluid overload.